Issue 2/2025
Gabrovska, N., Spasova, A., Khan, N., Velizarova, S.
Pulmonology Clinic, SBALDB “Prof. I. Mitev” – Sofia
RSV is a widespread human pathogen that causes frequent re-infections. 90% of children are infected with the virus in the first 2 years of life with frequent re-infections in older populations. Approximately 33 million cases are reported annually in children with 3 million hospitalizations and 120,000 deaths from complications related to the infection. RSV infections show seasonal variations in different geographical areas of the world. Premature infants, patients with pre-existing cardiac, pulmonary, neurological, immunosuppressive disorders and the elderly constitute the population at risk of morbidity and mortality. There is no specific vaccine for this type of infection. Treatment is symptomatic. Compliance with certain prevention rules can limit the spread and severity of the disease. There are risk groups that require special attention and the use of palivizumab as an effective means of preventing the severe course of RSV infection, in order to reduce mortality and hospitalizations in this group.
Address for correspondence:
Dr. N. Gabrovska, MD
SBALDB „Prof. I. Mitev“ – Pulmonology Clinic
11 „Academician Ivan Evstratiev Geshov“ Blvd.
1606, Sofia